The EC has approved argenx’s Vyvgart (efgartigimod alfa) 1000mg as a single agent for subcutaneous injection to treat CIDP.

Telitacicept is a dual-targeting agent that attaches to and blocks the effects of 2 key signaling proteins, B-lymphocyte ...

RemeGen Co., Ltd. ("RemeGen", stock symbols: 688331.SH/09995.HK) announced that telitacicept (RC18; brand name: 泰爱®) has received Orphan Drug Designation (ODD) from European Medicines Agency (EMA) for ...

UCB, a global biopharmaceutical company, today announced that 15 scholarships were awarded to people impacted by myasthenia gravis in the U.S. The UCB Myasthenia Gravis Scholarship™ exemplifies UCB's ...

The first patient enrolled in a planned international clinical trial has been treated at HonorHealth Research Institute with a new type of immune therapy for those with a rare muscle-weakness disease ...

SCOTTSDALE, Ariz. — June 16, 2025 — The first patient enrolled in a planned international clinical trial has been treated at HonorHealth Research Institute with a new type of immune therapy for those ...

The National Institute for Health and Care Excellence (NICE) recommended the drug not be used by the NHS due to its ...

People have been let down by a system that continues to put up barriers to accessing treatments that could significantly ...

Bringing this interview with Marla Black Morgan, MD, to a close, she looks to the future of research in both myasthenia ...

Among 47 patients with any of several forms of idiopathic inflammatory myositis (IIM) who took efgartigimod (Vyvgart Hytrulo) ...

In today’s Health Headlines, June is Myasthenia Gravis Awareness Month. What is myasthenia gravis, how is it diagnosed, and ...